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Introduction: Depression is frequent in ankylosing spondylitis (AS) patients. However, epidemiological data about
the potential increase in risk are lacking. This study compares the rate of doctor-diagnosed depression in a well
defined cohort of AS patients to the general population seeking care.
Methods: The Skåne Healthcare Register comprises healthcare data of each resident in Region Skåne, Sweden
(population 1.2 million), including ICD-10 diagnoses. Using physician coded consultation data from years 1999 to
2011, we calculated depression consultation rates for all AS patients. We obtained standardized depression-rate
ratios by dividing the observed depression rate in AS patients by the expected rate based on the corresponding
age- and sex-specific rates of depression in the general population seeking care. A ratio >1 equals a higher rate of
depression among AS patients.
Results: The AS cohort consisted of 1738 subjects (65% men) with a mean age of 54 years. The reference
population consisted of 967,012 subjects. During the 13-year observation period 10% (n = 172) of the AS cohort
had a doctor-diagnosed depression compared to 6% (n = 105) to be expected. The standardized estimate of
depression-rate ratio was 1.81 (95% confidence interval 1.44 to 2.24) in women men and 1.49 (1.20 to 1.89) in men.
Conclusions: The rate of doctor-diagnosed depression is increased about 80% in female and 50% in male AS
patients. Future challenges are to timely identify and treat the AS patients who suffer from depression.Introduction
The prevalence of ankylosing spondylitis (AS) in the
Western world is estimated to be 0.1 to 0.2%, with an esti-
mated incidence of 7/100,000 per year [1-3]. Due to the
nature of the disease, AS typically affects physical func-
tion, quality of life [4,5], and work productivity [6,7]. Co-
morbid conditions, including uveitis, inflammatory bowel
and cardiovascular disease, contribute to the prognosis
and total burden of AS [8].
Clinical depression has also been reported to be more
frequent in chronic diseases [9], rheumatic diseases in
general [10] and AS [11-13]. However, an estimate of
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stated.dependency, of depression in AS patients is lacking.
Therefore, our objective was to study consultation rates
of doctor-diagnosed depression in female and male AS
patients compared to the general population seeking
healthcare in a population-based open cohort study. We
hypothesized that the consultation rates of depression
are significantly higher in AS patients.Methods
The Skåne healthcare register (SHR)
Detailed information about the SHR is provided in previ-
ous articles [8,14]. In brief, each single healthcare consult-
ation in this region generates data entries by the healthcare
provider that are transferred to central databases by the pa-
tient’s unique 10-digit personal identification number. Data
includes information about date of consultation and inter-
national classification of disease (ICD)-10 diagnostic codesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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computer-based medical records.
The Swedish Population Register
The Swedish Population Register is the civil registration
of vital events (for example, births, deaths, removal) of
Swedish inhabitants. For this study, we linked SHR data
via the personal identification number to add informa-
tion on date of death and residency.
Inclusion criteria for the AS cohort
We required all AS cases to be at least 20 years of age
and to be resident in Skåne Region by the first health-
care visit in the SHR between 1999 and 2011. Further,
our case definition required a clinic visit with a diagnosis
of AS (ICD-10 code M45) made by a physician during
the years 1999 to 2011 (13 calendar years), at least once
at a rheumatology clinic or internal medicine clinic, or
at least twice at any other clinic including general prac-
tice. The date of fulfilling the above definition marked
the beginning of the exposure time. A previous validation
of spondyloarthritis at large, showed 98% of patients
identified via the register to be valid spondyloarthritis
patients [2].
Inclusion criteria for the reference population
In this article the general population seeking healthcare
is regarded as the reference population. For the AS co-
hort, we required all subjects in the reference population
to be residents in Skåne Region and aged 20 years or
older by the first healthcare visit registered in the SHR
between 1999 and 2011. Then we required all of the
subjects to have had at least one clinic visit between 1
January 1999 and 31 December 2011, with any diagnosis
by any physician in the SHR, to minimize confounding.
Outcome
For the reference population we calculated each single
subject’s person-time from the first healthcare visit until
one of the following four events had occurred for the first
time within the observation period from the first visit until
31 December 2011, in the following order of priority: 1)
occurrence of doctor-diagnosed depressive episode (ICD-
10 code F32) or recurrent depressive disorder (F33); 2)
death; 3) end of the observation period if the subject was
still a resident in the county by that time; or 4) date of re-
location outside of the region. The same procedure was
applied to the AS patients, where person-time was calcu-
lated from the date of fulfilling the AS definition.
Statistical analysis
Observed depression rate for AS patients
We calculated observed consultation rates for doctor-
diagnosed depression (depression rates) among patientsfulfilling our AS case criteria. The total number of AS
patients having had the diagnosis within the study period
formed the numerator of the rate, and the AS patients’
added person-time formed the denominator of the rate.
The age of all subjects was defined as the age at the mean
follow-up time. We calculated rates for each age and sex
stratum (using 5-year age categories).Expected depression rate for AS patients
We calculated the expected doctor-diagnosed depression
rate as if the rate in the general population seeking
healthcare prevailed, using age and sex of the AS pa-
tients as the standard. Hence, using data from the SHR,
we calculated the sum of each resident’s person-time
and counted all subjects diagnosed with the first occur-
rence of depression during the study period. We then
calculated the expected depression rate by multiplying the
stratum-specific rates in the reference population with the
appropriate age and sex weightings from the AS cohort.
Then we added the stratum-specific products to obtain
the age- and sex-standardized rate.Standardized depression-rate ratio and absolute rate
difference
We calculated age- and sex-standardized depression-rate
ratio by dividing the observed morbidity rate in the AS
cohort by their expected morbidity rate. A rate ratio >1
equals a higher depression rate in the AS cohort than in
the general population seeking healthcare. We calculated
95% CI for the rate ratios using the method described by
Breslow [15]. We also calculated the absolute depression-
rate difference (observed rate minus expected rate) to pro-
vide results of excess doctor-diagnosed depression on the
absolute scale as well.Gender differences
To evaluate the difference in depression-rate ratio in
women and men for AS patients and the reference popu-
lation, respectively, we also calculated the ratio of these
rate ratios with their 95% CI.Diabetes mellitus
To facilitate interpretation of the results obtained for the
AS patients, we also evaluated patients with another
chronic disease reported to be associated with increased
risk of depression, insulin-dependent and non-insulin-
dependent diabetes mellitus (ICD-10 code E10 or E11)
[16]. Our case definition for diabetes required a clinic visit,
with a physician's diagnosis of diabetes at least once at an
endocrinology or internal medicine clinic, or at least twice
at any other clinic, including general practice.
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The study was conducted according to the Declaration
of Helsinki and was approved by the Ethical Review
Board of Lund University, Sweden. The population in the
Skåne region was informed of the study via regional news
press and offered the opportunity to opt out, a process
sanctioned by the Ethical Review Board. Thus, no indi-
vidually signed informed consent forms were required ac-
cording to the decision from the Ethical Review Board (a
common procedure in Sweden for population-based regis-
ter studies).Results
The number of residents (aged ≥20 years) in Skåne Region
who fulfilled our AS case criteria during our 13-year study
period was 1,738 (64.4% men), mean age (SD) 54.5 (14.3)
years (1,275 AS patients (73%) had been diagnosed at a
rheumatology or internal medicine clinic). The total adult
general population seeking healthcare during the same
period consisted of 967,012 subjects (47.6% men).
During the study period 10% (n = 172) of the AS cohort
had at least one episode of doctor-diagnosed depression
compared to the expected 6% (n = 105) based on age- and
sex-standardized data from the reference population. The
standardized depression-rate ratio in subjects with AS
(Table 1) was significantly elevated (1.63; 95% CI 1.40,
1.89). The standardized depression-rate ratio in women
(1.81; 95% CI 1.44, 2.24) and in men (1.49; 95% CI 1.20,
1.89) were both elevated. However, the age-standardized
ratio between these rate ratios (women versus men) was
not significantly different (1.20; 95% CI 0.89, 1.62), imply-
ing no substantial interaction between AS and sex for the
risk of doctor-diagnosed depression.
The absolute rate difference (observed minus expected)
for doctor-diagnosed depression in subjects with AS was
649 per 100,000 person-years. The absolute rate differenceTable 1 Doctor-diagnosed depression in ankylosing spondylit










Men, all 6,983 89 1,275 60
≤50 years 2,879 42 1,376 27
>50 years 4,104 47 1,155 31
Women, all 3,259 83 2,547 46
≤50 years 1,274 39 2,825 20
>50 years 1,984 44 2,244 25
Total, all 10,242 172 1,679 105
≤50 years 4,153 83 1,825 47
>50 years 6,089 89 1,512 56
1AS patients diagnosed with depression (ICD-10 code F32 or F33) in 1999 to 2011.was greater in women (1,138 per 100,000 person-years)
compared to men (421 per 100,000 person-years). How-
ever, this difference is explained by the much higher ob-
served depression rate in women in general compared to
men (Table 1). The rate of doctor-diagnosed depression in
women in the reference population was highly elevated
compared to men (standardized depression rate ratio =
1.66; 95% CI 1.63, 1.68), that is, women had a 66% higher
increased rate than men. The standardized depression-
rate ratio in subjects with diabetes mellitus was signifi-
cantly elevated (1.67; 95% CI 1.63, 1.71).Discussion
In a cohort study design, using comprehensive population-
based epidemiologic data based on physicians’ diagnostic
coding, our hypothesis that consultation rates of depres-
sion are significantly higher in AS patients was confirmed.
We found an 80% increased rate of doctor-diagnosed de-
pression in women with AS and 50% in men with AS com-
pared to the general population seeking care. The higher
rate in women is due to general sex differences and thus is
not so much AS-specific. Although these findings come as
no surprise, population-based epidemiologic estimates of
the actual increase in risk and potential age and gender
aspects are lacking. These findings enhance our under-
standing of the total burden for AS patients and may
contribute to improved health assessment and treat-
ment planning [17].
Prior studies have suggested a relationship between
depression and rheumatic diseases [10] and AS [11,13].
In the present study we found evidence that the risk for
depression is higher in AS patients, and the increase is
in line with patients with diabetes mellitus. We further
found the absolute rate of doctor-diagnosed depression
to be much higher in women than men, both in the gen-








Rate ratio3 95% CI
853 421 1.49 1.20, 1.89
933 443 1.47 1.10, 1.93
759 396 1.52 1.07, 2.10
1,409 1,138 1.81 1.44, 2.24
1,546 1,279 1.83 1.35, 2.42
1,260 984 1.78 1.24, 2.48
1,030 649 1.63 1.40, 1.89
1,123 702 1.63 1.32, 1.98
923 588 1.64 1.28, 2.06
2Per 100,000 person-years. 3Bold figures indicate statistically significant results.
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the general population [18] and in patients with rheum-
atic diseases [10].
In our study, we did not include person-time for resi-
dents not seeking healthcare in the study time frame. In-
cluding such person-time would elevate the rate ratios
even further. This decision was made to compensate for
bias caused by tendency to consult (irrespective of reason)
being higher in patients with previous consultations. Still,
we cannot fully exclude the possibility of residual doctors’
work-up bias towards patients with a chronic disease such
as AS. However, we find this unlikely because depression
is not a typical diagnosis for which patients are screened,
unlike hypertension, hypercholesterolemia, or diabetes.
Furthermore, we included both prevalent and incident dis-
ease, both for the AS diagnosis and for depression, and
data have not been controlled for possible confounding
factors other than age and sex, and propensity to seek
care. Further, in this study we could not relate the risk
to disease duration, disease severity or other covariates,
therefore residual confounding is possible. Moreover,
the use of diagnostic codes based on physicians coding
in everyday practice might pose a threat to the validity.
However, the accuracy of the diagnostic coding from
the SHR has previously been validated for spondyloar-
thritis, as well as specifically for psoriatic arthritis and
psoriasis, with positive predictive values consistently ex-
ceeding 81% [19]. The diagnostic coding of depression
could not be externally verified, for example, by review
of medical records, due to restrictions in the approval of
our institutional review board.
Conclusions
Based on our findings, we conclude that the consultation
rate for depression is increased by more than 60% in AS
patients compared to the background population seeking
care, with women having somewhat larger increase in
risk. One future challenge is to timely identify AS patients
with depression. Research should focus on finding out
which patient-reported outcome measures are most suit-
able to identify a depressive disorder in AS patients. The
Hospital Anxiety and Depression Scale, the Hamilton
Rating Scale for Depression, the Beck Depression Inven-
tory, or the Center for Epidemiologic Studies Depression
Scale [10] could be considered, as these have previously
been used to asses depression in studies of rheumatic
disorders.
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